Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease | Zendy

Teddy Kosoglou | Zendy; Hubbell | Zendy; Xuan | Zendy; Cutler | Zendy; Meehan | Zendy; Kantesaria | Zendy; Wittner | Zendy

Open Access

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

Author(s) -

Teddy Kosoglou,

Hubbell,

Xuan,

Cutler,

Meehan,

Kantesaria,

Wittner

Publication year - 2013

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s36592

Subject(s) - mometasone furoate , medicine , dry powder inhaler , formoterol , metered dose inhaler , crossover study , inhaler , copd , pharmacokinetics , formoterol fumarate , asthma , adverse effect , inhalation , anesthesia , pharmacology , corticosteroid , budesonide , alternative medicine , pathology , placebo

Coadministration of mometasone furoate (MF) and formoterol fumarate (F) produces additive effects for improving symptoms and lung function and reduces exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the relative systemic exposure to MF and characterized the pharmacokinetics of MF and formoterol in patients with COPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research